Home » Stocks » Caladrius Biosciences

Caladrius Biosciences, Inc. (CLBS)

Stock Price: $2.24 USD 0.09 (4.19%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $2.27 +0.03 (1.34%) Aug 14, 7:52 PM

Stock Price Chart

Key Info

Market Cap 34.84M
Revenue (ttm) n/a
Net Income (ttm) -7.25M
Shares Out 15.55M
EPS (ttm) -1.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $2.24
Previous Close $2.15
Change ($) 0.09
Change (%) 4.19%
Day's Open 2.33
Day's Range 2.19 - 2.44
Day's Volume 932,844
52-Week Range 1.05 - 3.64

More Stats

Market Cap 34.84M
Enterprise Value n/a
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 15.55M
Float 7.81M
EPS (basic) -0.83
EPS (diluted) -1.81
FCF / Share -0.64
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 169,966
Short Ratio 0.22
Short % of Float 1.77%
Beta 1.58
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.10
Revenue n/a
Operating Income -18.50M
Net Income -7.25M
Free Cash Flow -8.43M
Net Cash 34.89M
Net Cash / Share 2.24
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -38.54%
ROE -73.77%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$10.50*
(368.75% upside)
Low
6.00
Current: $2.24
High
18.50
Target: 10.50
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----22.4917.9414.6714.3310.0569.82
Revenue Growth----25.36%22.3%2.36%42.58%-85.61%-
Gross Profit----2.332.261.722.381.4020.15
Operating Income-20.09-16.99-27.59-29.50-114-57.74-36.81-30.39-34.00-18.88
Net Income-19.36-16.1722.98-32.66-80.89-54.87-38.98-53.77-47.13-23.31
Shares Outstanding10.339.698.976.554.853.282.051.380.890.52
Earnings Per Share-1.88-1.672.56-4.99-16.67-16.80-19.00-40.00-54.00-46.00
Operating Cash Flow-18.88-19.99-20.88-23.67-39.26-46.90-27.10-13.85-20.93-8.48
Capital Expenditures--0.13-0.14-1.10-3.19-3.66-2.69-0.53-0.57-16.38
Free Cash Flow-18.88-20.12-21.01-24.77-42.44-50.55-29.79-14.38-21.50-24.85
Cash & Equivalents25.1643.0560.097.0820.3226.2546.1313.743.9418.99
Total Debt--0.166.3716.7816.644.153.813.7812.60
Net Cash / Debt25.1643.0559.930.703.549.6141.989.920.156.39
Assets27.1544.5863.3853.5157.2112689.8254.41155143
Liabilities6.607.1313.1930.0533.9268.2027.7921.5975.2056.54
Book Value20.8237.7350.514.8823.7158.5162.5433.1862.0348.66
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Caladrius Biosciences, Inc.
Country United States
Employees 27
CEO David J. Mazzo

Stock Information

Ticker Symbol CLBS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CLBS

Description

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. Its product candidates include developmental treatments for cardiovascular diseases, such as CLBS12 for the treatment of critical limb ischemia; CLBS16, which is in Phase II clinical trial for the treatment of coronary microvascular dysfunction; CLBS14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in Basking Ridge, New Jersey.